https://orcid.org/0009-0000-6513-5940
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Aim
This study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) in China.
Methods
A retrospective study was conducted using electronic medical records (EMR) of patients with prostate cancer from three tertiary-care hospitals in China between January 2014 and March 2021. Descriptive statistics were used to analyze study outcomes.
Results
In total, 1086 patients with mHSPC and 679 patients with nmCRPC were included. From 2015 to 2020, the annual percentage of prevalent and incident cases of mHSPC decreased from 22.4% to 20.0% and 11.1% to 6.9%, respectively; for nmCRPC, these increased from 3.8% to 13.6% and 3.3% to 8.4%. Androgen-deprivation therapy and first-generation antiandrogens (bicalutamide or flutamide) were the most frequently prescribed prostate cancer–related medications at baseline and follow-up in patients with mHSPC. Bicalutamide was the most frequently prescribed prostate cancer–related medication during follow-up in patients with nmCRPC. For mHSPC, inpatient admission costs were the highest, with the median (interquartile range) costs per person-month being USD 403.00 (USD 85.50–1226.20), whereas outpatient visit costs were the highest for nmCRPC (USD 372.60 [USD 139.50–818.50]).
Limitations
EMR-based study design did not capture treatment patterns, HRU and associated costs, and healthcare encounters that occurred outside of participating hospitals, which could have led to underestimation of the true disease burden.
Conclusions
A contrasting trend of a decline in the prevalence and incidence of mHSPC and an increase in these for nmCRPC was observed between 2015 and 2020 in China. Androgen-deprivation therapy and first-generation antiandrogens were the most frequently prescribed prostate cancer–related medications. Healthcare resource utilization was driven by inpatient costs in mHSPC and outpatient costs in nmCRPC.
Transparency
Declaration of financial/other relationships
YW, CL, CL, and YN received research funding from Astellas Pharma Inc. and Pfizer Inc. for this study. YL is an employee of Astellas, China; LB is an employee of Evidera, a business unit of PPD, a Thermo Fisher Scientific company, which was contracted by Astellas for the conduct of this study.
Author contributions
All the authors were involved in the conception and/or design of the work, acquisition of data, data analysis, and/or interpretation of data. All authors had access to the study results, reviewed and revised the manuscript, and approved the final draft submitted for publication.
Acknowledgements
The authors would like to thank Leena Patel, Chrysi Petraki, and Rucha Kurtkoti from IQVIA for medical writing and editorial support.
Data availability statement
The datasets used during this study are not publicly available due to local data access policy but may become available from the corresponding author upon reasonable request.
Previous presentation
A poster presenting part of this work titled “Real-World Treatment Patterns (TxP) and Healthcare Resource Utilization (HRU) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) in China” was presented at ISPOR 2023, Boston, MA, USA (May 7–10, 2023).
Ethical oversight/IRB approval/patient consent
IRB approval was obtained at each participating hospital.